DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for middle ear disorder — screening already-approved drugs against its 14-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleMiddle ear disorder maps to a 14-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for middle ear disorder is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
ABO, alpha 1-3-N-acetylgalactosaminyltransferase and alpha 1-3-galactosyltransferase (ABO) — ABO is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet 6-deoxy-alpha-l-galactopyranosyldrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 4Y63 · 1.3 Å · ligand octyl 2-O-(6-deoxy-alpha-L-galactopyranosyl)-beta-D-galactopyranoside (BHE). Experimental structure, not a prediction.
What the evidence adds up to
The 1962 review notes that the anatomy, physiology and pathology of the middle ear had been fairly well explored by that time, and that enough knowledge had accumulated to allow advances in medical and surgical treatment of middle-ear disease, with preservation and restoration of serviceable hearing in many cases previously considered hopeless. The 2010 review describes the middle ear as a composite organ formed from all three germ layers and the neural crest, and notes that non-mammalian vertebrates have a single ossicle (the columella) while mammals have three (malleus, incus, stapes). That review states that genetic studies are beginning to unravel the induction and patterning of the multiple middle ear elements, but that future studies elucidating integrated spatio-temporal signalling mechanisms are needed.
The 2021 study examined Id1−/−; Id3+/− and Id1+/−; Id3−/− mice and found a high incidence (greater than 50%) of middle ear infection in these compound mutant mice. The mutant mice demonstrated hearing impairment starting around 30 days of age, with elevated auditory brainstem response thresholds compared to littermate controls, and much lower distortion product otoacoustic emission amplitudes, indicating compromised sound transduction in the middle ear. The authors conclude that Id1/Id3 compound mutant mice are a novel model for human otitis media.
The 2014 study describes the edison mouse model of chronic otitis media, generated by ENU mutagenesis. Homozygous edison mice have craniofacial abnormalities, an emphysema-like lung phenotype, and spontaneously develop conductive hearing loss at 28 days as measured by ABR. Histological analysis shows the hearing loss is associated with chronic OM characterised by mucosal inflammation and highly cellular ear exudates. A putative functional mutation was identified, resulting in a missense Leu972Pro change in the Nisch gene. The study reports that mice heterozygous for Itga5-null and homozygous for edison alleles show a significantly increased penetrance and severity of chronic OM, and that analysis of downstream pathways suggests the edison allele impacts both RAC1 and TGF-β/SMAD signalling. The edison mouse was identified as a robust model for bacterial NTHi infection.
What is still missing is the translation of these genetic mouse models into human therapies. No drug treatment is tested or proposed in any of these abstracts. The 1962 review mentions medical and surgical treatment advances, but gives no specific drugs or outcomes. The genetic pathways identified (Id proteins, Nisch, Itga5, RAC1, TGF-β/SMAD) remain at the stage of basic biology. No clinical trial, no patient stratification strategy, and no funding for a drug-repurposing programme in human middle ear disorders is described.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Frontiers in bioscience · 2010 · 43 citations
Can you hear me now? Understanding vertebrate middle ear development
AbstractThe middle ear is a composite organ formed from all three germ layers and the neural crest. It provides the link between the outside world and the inner ear, where sound is transduced and routed to the brain for processing. Extensive classical and modern studies have described the complex morphology and origin of the middle ear. Non-mammalian vertebrates have a single ossicle, the columella. Mammals have three functionally equivalent ossicles, designated the malleus, incus and stapes. In this review, I focus on the role of genes known to function in the middle ear. Genetic studies are beginning to unravel the induction and patterning of the multiple middle ear elements including the tympanum, skeletal elements, the air-filled cavity, and the insertion point into the inner ear oval window. Future studies that elucidate the integrated spatio-temporal signaling mechanisms required to pattern the middle ear organ system are needed. The longer-term translational benefits of understanding normal and abnormal ear development will have a direct impact on human health outcomes.
Archives of Otolaryngology - Head and Neck Surgery · 1962 · 37 citations
Auditory Function and Intracranial Lesions
AbstractThe development of the specialty of otology has followed the accumulation of knowledge in anatomy, physiology, and pathology. The course of this development has proceeded from the external ear, through the middle ear, to the inner ear, neural pathways, and cerebral cortex. In the past the anatomy, physiology, and pathology of the middle ear has been fairly well explored. There are still many things to learn about this area, but enough knowledge has accumulated to allow exciting advances in recent years both in medical and in surgical treatment of middle-ear disease, and this has constituted a true renaissance in middle-ear therapy with preservation and restoration of serviceable hearing in many cases that previously would have been considered hopeless. This area has been the easiest to study, and therefore, the first to be thoroughly explored. The areas of the inner ear and central pathways, being much more inaccessible, have necessarily lagged
Frontiers in Genetics · 2021 · 2 citations · open access
Hearing Loss in Id1−/−; Id3+/− and Id1+/−; Id3−/− Mice Is Associated With a High Incidence of Middle Ear Infection (Otitis Media)
AbstractInhibitors of differentiation/DNA binding (Id) proteins are crucial for inner ear development, but whether Id mutations affect middle ear function remains unknown. In this study, we obtained Id1 −/− ; Id3 +/− mice and Id1 +/− ; Id3 −/− mice and carefully examined their middle ear morphology and auditory function. Our study revealed a high incidence (>50%) of middle ear infection in the compound mutant mice. These mutant mice demonstrated hearing impairment starting around 30 days of age, as the mutant mice presented elevated auditory brainstem response (ABR) thresholds compared to those of the littermate controls. The distortion product of otoacoustic emission (DPOAE) was also used to evaluate the conductive function of the middle ear, and we found much lower DPOAE amplitudes in the mutant mice, suggesting sound transduction in the mutant middle ear is compromised. This is the first study of the middle ears of Id compound mutant mice, and high incidence of middle ear infection determined by otoscopy and histological analysis of middle ear suggests that Id1/Id3 compound mutant mice are a novel model for human otitis media (OM).
Oxford University Research Archive (ORA) (University of Oxford) · 2014 · 0 citations · open access
edison - a novel model of otitis media
AbstractOtitis media (OM) is characterised by inflammation of the middle ear and is a common cause of conductive hearing impairment that places a substantial social, medical and economic burden on healthcare systems globally. Despite the importance of the disease, the aetiology of chronic middle ear inflammatory disease remains poorly understood. The development and persistence of chronic OM is multi-factorial with a significant genetic component. A new mouse model of chronic OM, <em>edison</em>, was generated by <em>N</em>-ethyl-<em>N</em>-nitrosourea (ENU) mutagenesis and discovered in a recessive screen at MRC Harwell. Homozygous <em>edison</em> mice have craniofacial abnormalities, an emphysema-like lung phenotype and spontaneously develop a conductive hearing loss at 28 days as measured by ABR. Histological analysis shows the hearing loss is associated with the development of chronic OM in the middle ear, characterised by mucosal inflammation and highly cellular ear exudates. Similar to the <em>Jeff</em> and <em>Junbo</em> mutants, <em>edison</em> shows raised levels of <em>Vegfa</em>, <em>Tnfα</em> and <em>Il-1β</em> in middle ear fluids. A putative functional mutation was identified, resulting in a missense Leu972Pro change in a relatively unknown gene, <em><em>Nisch</em>arin</em> (<em>Nisch</em>). The identification of additional ENU-induced <em>Nisch</em> alleles, and subsequent characterisation, validated <em>Nisch</em> as the causative gene in <em>edison</em>. NISCH selectively binds ITGA5, which is thought to have a role in modulating VEGF signalling through SRC and FAK kinases. A significant genetic interaction between <em>Nisch</em> and <em>Itga5</em> exists and impacts upon development of chronic OM. Mice heterozygous for <em>Itga5</em>-null and homozygous for <em>edison</em> alleles show a significantly increased penetrance and severity of chronic OM. Analysis of downstream pathways suggests that the <em>edison</em> allele is impacting upon both RAC1 and TGF-β/SMAD signalling. I also explored the potential use of the <em>edison</em> mouse as a model for bacterial challenge with the human otopathogen, NT<em>Hi</em>. Similar to the <em>Junbo</em> infection model at MRC Harwell, the <em>edison</em> mouse was identified as a robust OM model for bacterial NTHi infection. The <em>edison</em> mouse highlights a new candidate gene for susceptibility to chronic OM and will provide further insight into the genetic pathways and pathogenic processes involved in chronic OM.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
